CN110960558A - A kind of preparation method of Akk bacteria animal capsules related to metabolic diseases - Google Patents
A kind of preparation method of Akk bacteria animal capsules related to metabolic diseases Download PDFInfo
- Publication number
- CN110960558A CN110960558A CN201911355192.7A CN201911355192A CN110960558A CN 110960558 A CN110960558 A CN 110960558A CN 201911355192 A CN201911355192 A CN 201911355192A CN 110960558 A CN110960558 A CN 110960558A
- Authority
- CN
- China
- Prior art keywords
- capsule
- akk bacteria
- preparation
- akk
- capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 73
- 241000894006 Bacteria Species 0.000 title claims abstract description 69
- 241001465754 Metazoa Species 0.000 title claims abstract description 36
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 26
- 108010010803 Gelatin Proteins 0.000 claims abstract description 17
- 239000008273 gelatin Substances 0.000 claims abstract description 17
- 229920000159 gelatin Polymers 0.000 claims abstract description 17
- 235000019322 gelatine Nutrition 0.000 claims abstract description 17
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 17
- 239000000706 filtrate Substances 0.000 claims abstract description 14
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 12
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 12
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 12
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 12
- 239000007901 soft capsule Substances 0.000 claims abstract description 11
- 238000003756 stirring Methods 0.000 claims abstract description 11
- 239000006187 pill Substances 0.000 claims abstract description 8
- 239000000084 colloidal system Substances 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002609 medium Substances 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 22
- 102000015728 Mucins Human genes 0.000 claims description 18
- 108010063954 Mucins Proteins 0.000 claims description 18
- 229920001817 Agar Polymers 0.000 claims description 13
- 208000008589 Obesity Diseases 0.000 claims description 13
- 239000008272 agar Substances 0.000 claims description 13
- 235000020824 obesity Nutrition 0.000 claims description 13
- 238000010790 dilution Methods 0.000 claims description 12
- 239000012895 dilution Substances 0.000 claims description 12
- 210000003608 fece Anatomy 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000011573 trace mineral Substances 0.000 claims description 8
- 235000013619 trace mineral Nutrition 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000007640 basal medium Substances 0.000 claims description 6
- 208000016097 disease of metabolism Diseases 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- -1 polyethylene Polymers 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 102000009338 Gastric Mucins Human genes 0.000 claims description 4
- 108010009066 Gastric Mucins Proteins 0.000 claims description 4
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 235000019270 ammonium chloride Nutrition 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- 238000012869 ethanol precipitation Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 4
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 210000004767 rumen Anatomy 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229940048181 sodium sulfide nonahydrate Drugs 0.000 claims description 4
- WMDLZMCDBSJMTM-UHFFFAOYSA-M sodium;sulfanide;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[SH-] WMDLZMCDBSJMTM-UHFFFAOYSA-M 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 238000012136 culture method Methods 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 238000009928 pasteurization Methods 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 238000009413 insulation Methods 0.000 claims 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 28
- 238000007873 sieving Methods 0.000 abstract description 10
- 238000005303 weighing Methods 0.000 abstract description 9
- 238000002844 melting Methods 0.000 abstract description 6
- 230000008018 melting Effects 0.000 abstract description 6
- 238000002054 transplantation Methods 0.000 abstract description 6
- 238000000227 grinding Methods 0.000 abstract description 5
- 238000010438 heat treatment Methods 0.000 abstract description 5
- 238000003825 pressing Methods 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 238000005406 washing Methods 0.000 abstract description 3
- 229940100691 oral capsule Drugs 0.000 abstract 1
- 229940023488 pill Drugs 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 241000702462 Akkermansia muciniphila Species 0.000 description 15
- 238000011160 research Methods 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 230000001276 controlling effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 241000792859 Enema Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 239000007920 enema Substances 0.000 description 3
- 229940095399 enema Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 241000702460 Akkermansia Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 241001272701 Akkermansiaceae Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of capsule preparation, and discloses a preparation method of Akk bacteria animal capsules related to metabolic diseases, which is characterized in that 60 percent of conjugated linoleic acid, 15 percent of L-carnitine and 25 percent of Akk bacteria are weighed and placed in a mixing tank for stirring; grinding in a colloid mill for three times, and sieving with a 100-mesh sieve to obtain a content material; placing the mixture in a vacuum pan to remove gas in the material; weighing gelatin, water and glycerol according to a ratio of 100:40:100, feeding into a gelatin melting tank, heating to 60-75 ℃, after the gelatin is completely melted, decompressing, vacuumizing, and sieving with a 80-mesh sieve to obtain a capsule filtrate; sending the filtrate of the capsule body and the materials of the content into a pill press according to the weight ratio of 1:2, and pressing into soft capsules; washing off oil stain on the surface of the capsule, selecting and removing non-positive pills to obtain positive soft capsule, and refrigerating at low temperature for storage. The oral capsule is used for flora transplantation, the composition of intestinal flora of animals with metabolic diseases is adjusted, and the control and treatment of the metabolic diseases are realized.
Description
Technical Field
The invention belongs to the technical field of capsule preparation, and particularly relates to a preparation method of Akk bacteria animal capsule related to metabolic diseases.
Background
Currently, the closest prior art: the intestinal flora refers to tens of thousands of microorganisms living in our intestines, including prokaryotes, eukaryotes, and archaea. The metagenome is different from the flora, and refers to the presence of more than 10 times the number of human genes in all gut flora. The intestinal flora is closely related to human health, and microorganisms residing in the human intestinal tract are key factors of host metabolism and are considered as potential sources of new therapies. A number of recent papers and reviews cover different aspects of the microbiome and its potential role in human health, including early in life, but also specific diseases such as cardiometabolic disorders, inflammatory bowel diseases, neuropsychiatric diseases and cancer, etc.
Akkermansia muciniphila (Akk bacteria) is a bacterium capable of degrading mucin in human intestinal tracts, and research shows that the Akkermansia muciniphila is negatively related to obesity, diabetes, inflammation and metabolic disorder; the mechanism of the probiotic effect can be to regulate the thickness of mucus in the intestinal tract and maintain the integrity of intestinal tract barrier and other regulation effects on endocrine; especially has good regulating effect on hyperglycemia and obesity; the content of Akk bacteria in intestinal tract of people with hyperglycemia and obesity is less than 1/100 bacteria of common people. There are studies that have shown pathogenic effects of the bacterium in reducing body fat mass, improving glucose homogeneity, reducing adipose tissue in inflammation and increasing gut integrity in mouse studies. In obese and type 2 diabetic mice, the abundance of Akk bacteria was reduced. And feeding with prebiotics normalized Akk germ abundance, which was associated with improvement in metabolites. It was also demonstrated that myxophilus treatment reversed high fat diet-induced metabolic disorders including increased fat mass, metabolic endotoxemia, adipose tissue flow and insulin resistance.
In some researches, A.muciniphila is separated from human excrement for the first time by using porcine intestinal mucin as a selective culture medium, and the A.muciniphila belongs to the Microbacterium verrucosum family by 16S rRNA gene sequencing analysis and is classified into the Akkermansiaceae family. Muciniphila is commonly colonized in human intestines, at least 8 different Akkermansia genera exist in intestinal mucus layers, and the a muciniphila of different genera is likely to be colonized in the same human intestines at the same time.
Akkermansia polyciniphila is a gram-negative strict anaerobic bacterium that colonizes the mucus layer of the gastrointestinal tract and specifically degrades mucin, which is isolated from human feces. Akk bacteria play an important role in the mucosal surface of the inner cavity of a host, can regulate the health of the organism and is gradually the focus of intestinal micro-ecology and probiotic research in recent years. Akk bacteria are among the most abundant members of the human intestinal microbiota, accounting for 1% to 5% of intestinal microorganisms. The diversity of intestinal flora is subject to great differences due to individual differences (age, diet, health, etc.) and is often reflected by the species, number, abundance, etc. of a genus.
The colonization of a. muciniphila also varies somewhat at different age stages: the number of A.muciniphila in the feces of young people is lower than that of the feces of old people, so that the old people probably pay more attention to body health and have more balanced diet; the abundance of a. mucini phila of centenarians in china is significantly weaker than that of people not in centenarians, and the abundance of european adults is higher than that of older people; the abundance and colonization rates of infants are lower than those of adults, but reach the adult level within one year. The correlation analysis of the age and the A.muciniphila needs further research, and the expansion of the sample size and the optimization of the detection technology are the primary problems. Due to different regions, the living environment and dietary structure of people are different, and the influence on the colonization of some flora is possible: the planting rate of Brazil population A. muciniphila is about 79.17%, European population is about 74.70%, and southern Chinese population is about 51.74%; mucini philia is less abundant in the stools of autistic children in australia than normal children, while the flora is more abundant in autistic children in italy and in the united states than normal children. The abundance of A.muciniphila in patients with intestinal inflammation diseases is lower than that of common people, and the quantity and the abundance of A.muciniphila in overweight or obese people and patients with type II diabetes are lower than that of common people. The quantity and the abundance of the A.muciniphila can be increased by controlling diet, taking prebiotics, losing weight surgery and other modes, the diversity of intestinal flora of athletes who exercise frequently is higher, the quantity of the A.muciniphila is obviously higher than that of obese people with abnormal metabolism, the reasonable diet, the work and rest rule and proper exercise can be used for keeping the quantity and the abundance of the A.muciniphila at a higher level, and the A.muciniphila can be indirectly proved to be used as a potential index for measuring the physical health condition.
Many studies on intestinal flora indicate that imbalance of intestinal flora (changes in the structure or functional structure of intestinal flora) can cause various diseases, such as obesity, diabetes, nervous system diseases, allergy, and various inflammations. There are studies showing that Akk bacteria are reduced in numbers during obesity and diabetes and that higher baseline abundance is significantly associated with improved cardiometabolic parameters in obese patients receiving heat limitation. It was found that daily administration of Akk bacteria grown on a mucus-based medium could counteract the development of High Fat Diet (HFD) -induced obesity and intestinal barrier dysfunction. Further, it has been found that Akk bacterium is associated with obesity, type II diabetes, and progressive frostbite, and therefore, Akk bacterium is negatively associated with metabolic diseases such as obesity and type II diabetes, and thus, administration of a drug containing Akk bacterium can provide a good therapeutic effect on the diseases.
Akk bacteria have been separated from human feces for the first time for more than 10 years, but most of the research is only limited to the physiological characteristics of Akk bacteria, and the research on the molecular action mechanism does not appear yet. Meanwhile, the optimization of the separation method is always in a standstill, and how to rapidly separate and classify the materials is always a bottleneck of research.
At present, the operation process of intestinal flora transplantation is mostly to irrigate the flora to be transplanted from the anus of an animal in an enema mode, and a test tube containing the flora can also be implanted into the animal body in an operation mode. Intestinal flora transplantation is becoming more and more common, because the intestinal flora in the animal body is disordered after the animal takes some antibacterial drugs, the state of the intestinal flora can be improved as soon as possible by the intestinal flora transplantation, and the occurrence of secondary reaction is prevented. However, the transplantation of the intestinal flora by means of enema cannot be controlled precisely in quantity and concentration gradient and is cumbersome to handle. Therefore, there is a need to develop a precise, effective and economical intestinal flora drug for metabolic disease animals.
In summary, the problems of the prior art are as follows:
(1) the existing research on Akk bacteria is only limited to the physiological characteristics of Akk bacteria, and the research on molecular action mechanisms does not appear. Meanwhile, the optimization of the separation method is always in a standstill, and how to rapidly separate and classify the materials is always a bottleneck of research. This makes the application of Akk bacteria in metabolic diseases slow.
(2) The existing intestinal flora transplanted in an enema form cannot accurately control the quantity and concentration gradient of the intestinal flora and is complicated to operate.
The difficulty of solving the technical problems is as follows: the method for extracting Akk bacteria with high efficiency and carrying out pure culture, and the method for preparing capsules.
The significance of solving the technical problems is as follows: akk bacteria are subjected to pure culture and prepared into capsules efficiently, and the intestinal flora of animals suffering from metabolic diseases is adjusted in an oral mode, so that the aims of controlling and treating the intestinal flora are fulfilled.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a preparation method of Akk bacteria capsule for animals, which is related to metabolic diseases.
The invention is realized by a preparation method of Akk bacteria capsule for animals related to metabolic diseases, and the preparation method of Akk bacteria capsule for animals comprises the following steps:
step one, weighing 60% of conjugated linoleic acid, 15% of L-carnitine and 25% of Akk bacteria by weight percent, placing the materials into a mixing tank, and uniformly stirring the materials.
Step two, grinding the uniformly stirred conjugated linoleic acid, L-carnitine and Akk bacteria in a colloid mill for three times, and sieving with a 100-mesh sieve to obtain a content material; then the content material is put into a vacuum pan, the vacuum degree is controlled to be-0.06 Mpa, and the gas in the material is removed.
Weighing the gelatin, the water and the glycerol according to the ratio of 100:40:100, feeding the materials into a gelatin melting tank, stirring and heating to 60-75 ℃, reducing pressure and vacuumizing after the gelatin is completely melted, sieving by a 80-mesh sieve to obtain capsule body filtrate, and placing the capsule body filtrate in a heat-preserving container for later use.
And step four, respectively feeding the capsule body filtrate obtained in the step three and the obtained content material into a pelleting press according to the weight ratio of 1:2, and pressing to obtain the soft capsule.
Step five, washing off oil stains on the surface of the capsule by using alcohol with the concentration of more than 90% in the capsule obtained in the step four; selecting the capsule with oil stain on the surface, removing non-positive pill to obtain positive soft capsule, and storing at 2-8 deg.C.
Further, in the fourth step, the temperature of the pelleting machine is controlled to be 24-28 ℃, the humidity is controlled to be 30-40%, and after static drying is carried out for 24 hours, the capsules are produced.
Further, the collection conditions of the Akk bacteria are as follows: collecting fresh feces of healthy people, sealing the bag, and storing for use.
Further, the screening conditions of the Akk strain are as follows: a. diarrhea did not occur in the last half year. b. Antibiotics have not been used in the last year. c. No history of intestinal disease or intestinal surgery. d. Without any infectious disease. e. Without any metabolic disease.
Further, the Akk bacteria extraction and pure culture method comprises the following steps:
(1) fresh fecal samples of healthy people were separately collected in a polyethylene bag and stored in a sealed condition for future use, and 0.5g of feces was diluted into 9ml of sterile anaerobic ringer's solution containing 0.5g of cysteine.
(2) The suspension obtained in step (1) was mixed thoroughly and diluted serially (10-fold) in ringer's solution. Each dilution (1ml) was then inoculated in triplicate into 9ml of bicarbonate buffer.
(3) All compounds except vitamins were autoclaved. To this basal medium 0.7% (v/v) of clear sterile rumen fluid and 0.25% (v/v) of commercial porcine gastric mucin were added and purified by ethanol precipitation. This medium is called mucin medium.
(4) Pure cultures were isolated using soft agar technique: the highest dilution of observed culture growth was serially diluted to 10 in phosphate buffer (pH7)-9Then 10 is put-6-10-9The dilutions were re-inoculated into the same medium containing 0.75% agar, individual target colonies were picked, allowed to grow in mucin medium, and re-inoculated into soft agar mucin medium.
(5) And (5) repeating the step (4) until purification.
Further, in step (2), the basal medium contains: 0.4g of monopotassium phosphate, 0.53g of sodium monohydrogen phosphate, 0.3g of ammonium chloride, 0.3g of sodium chloride, 0.1g of magnesium chloride hexahydrate, 0.11g of calcium chloride, 1ml of alkaline trace element solution, 1ml of acidic trace element solution, 1ml of vitamin solution, 0.5mg of resazurin, 4g of sodium bicarbonate and 0.25g of sodium sulfide nonahydrate.
Further, instead of mucin, soybean peptone at a concentration of 16g/L, threonine at a concentration of 4g/L and mixed sugars (glucose, N-acetylglucosamine) at a concentration of 25mM were used. Cultures were washed and concentrated under strictly anaerobic conditions with 25% (vol/vol) glycerol in anaerobic PBS. In addition, the same number of Akk bacteria grown on synthetic medium were inactivated by pasteurization at 70 ℃ for 30 minutes, after which the culture was immediately frozen and stored at-80 ℃.
The invention also aims to provide a capsule prepared by the preparation method of the Akk bacteria animal capsule related to the metabolic disease. Akk bacteria capsule belongs to a medicine for animals, and the capsule contains: conjugated linoleic acid, L-carnitine and Akk bacteria. The specific application of the capsule is that animals can treat metabolic diseases by taking the capsule orally.
It is another object of the present invention to provide a medicament for treating obesity in animals comprising the capsule.
Another object of the present invention is to provide a medicament for treating type ii diabetes comprising the capsule.
In summary, the advantages and positive effects of the invention are: the invention adopts pure culture of Akk bacteria under multiple strict conditions and makes the pure culture into capsules, and the oral capsules are used for flora transplantation to adjust the composition of intestinal flora of animals with metabolic diseases, thereby realizing the control and treatment of the diseases and achieving the purpose of treating the metabolic diseases of the animals, such as obesity, type II diabetes, and the like. The invention has the advantages of no toxicity, long-term effectiveness and the like.
Drawings
FIG. 1 is a flow chart of a preparation method of Akk bacteria capsule for animals relevant to metabolic diseases, which is provided by the embodiment of the invention.
FIG. 2 is a flow chart of the Akk bacteria extraction and pure culture method provided by the embodiment of the invention.
FIG. 3 is a flow chart of a Akk bacteria preservation method according to an embodiment of the present invention.
Fig. 4 is a flow chart of a preparation method of Akk bacteria capsule content provided by an embodiment of the invention.
Fig. 5 and fig. 6 are flow charts of Akk microcapsule body preparation methods provided by embodiments of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
In view of the problems in the prior art, the present invention provides a method for preparing Akk bacteria capsule for animals, which is related to metabolic diseases, and the present invention is described in detail below with reference to the accompanying drawings.
As shown in fig. 1, the preparation method of Akk bacteria capsule for animals related to metabolic diseases provided by the embodiment of the invention comprises the following steps:
s101: weighing 60% of conjugated linoleic acid, 15% of L-carnitine and 25% of Akk bacteria according to the weight percentage, placing the materials into a mixing tank, and uniformly stirring the materials.
S102: grinding the uniformly stirred conjugated linoleic acid, L-carnitine and Akk bacteria obtained in the step S101 in a colloid mill for three times, and sieving with a 100-mesh sieve to obtain a content material; then the content material is put into a vacuum pan, the vacuum degree is controlled to be-0.06 Mpa, and the gas in the material is removed.
S103: weighing gelatin, water and glycerol according to a ratio of 100:40:100, feeding into a gelatin melting tank, stirring and heating to 60-75 ℃, reducing pressure and vacuumizing after the gelatin is completely melted, sieving with a 80-mesh sieve to obtain capsule filtrate, and placing in a heat-insulating bucket for later use.
S104: and (4) respectively feeding the capsule body filtrate obtained in the step (S103) and the obtained content materials into a pelleting press according to the weight ratio of 1:2, and pressing to obtain the soft capsule. Controlling the temperature of the pelleting machine to be 24-28 ℃ and the humidity to be 30-40%, statically drying for 24 hours, and then pelleting the capsules.
S105: washing oil stains on the surface of the capsule by using alcohol with the concentration of more than 90% in the capsule obtained in the step S104; selecting the capsule with oil stain on the surface, removing non-positive pill to obtain positive soft capsule, and storing at 2-8 deg.C.
The technical solution of the present invention is further described with reference to the following examples.
Example 1
The embodiment of the invention provides a preparation method of Akk bacteria capsules for patients with metabolic diseases such as obesity, type II diabetes and the like, which comprises the following steps:
1. akk Collection and screening of bacteria
1.1 acquisition conditions: collecting fresh feces of healthy people, sealing the bag, and storing for use.
1.2 screening conditions: a. diarrhea did not occur in the last half year. b. Antibiotics have not been used in the last year. c. No history of intestinal disease or intestinal surgery. d. Has no infectious diseases, such as hepatitis A, hepatitis B, hepatitis C, etc. e. Has no metabolic diseases, such as diabetes, obesity, hypoglycemia, etc.
2. Akk extraction and pure culture of fungus
2.1 fresh stool samples from healthy persons were separately collected in a polyethylene bag and stored in a sealed condition, and 0.5g of stool was diluted into 9ml of sterile anaerobic ringer's solution containing 0.5g of cysteine. This suspension was mixed well and serially diluted (10-fold) in ringer's solution. Each dilution (1ml) was then inoculated in triplicate into 9ml of bicarbonate buffer. The basic culture medium contains: 0.4g of monopotassium phosphate, 0.53g of sodium monohydrogen phosphate, 0.3g of ammonium chloride, 0.3g of sodium chloride, 0.1g of magnesium chloride hexahydrate, 0.11g of calcium chloride, 1ml of alkaline trace element solution, 1ml of acidic trace element solution, 1ml of vitamin solution, 0.5mg of resazurin, 4g of sodium bicarbonate and 0.25g of sodium sulfide nonahydrate. To this basal medium 0.7% (v/v) of clear sterile rumen fluid and 0.25% (v/v) of commercial porcine gastric mucin were added and purified by ethanol precipitation. This medium is called mucin medium. Pure cultures were isolated using soft agar technique: growing the observed cultureThe highest dilution was serially diluted to 10 in phosphate buffer (pH7)-9Then 10 is put-6-10-9The dilutions were re-inoculated into the same medium containing 0.75% agar, individual target colonies were picked, allowed to grow in mucin medium, and re-inoculated into soft agar mucin medium. This step was repeated until purification (as shown in figure 2).
2.2 replacement of mucin by Soytone at a concentration of 16g/L, threonine at a concentration of 4g/L and mixed sugars of 25mM (glucose, N-acetylglucosamine). Cultures were washed and concentrated under strictly anaerobic conditions with 25% (vol/vol) glycerol in anaerobic PBS. In addition, the same number of Akk bacteria grown on synthetic medium were inactivated by pasteurization at 70 ℃ for 30 minutes, and then the culture was immediately frozen and stored at-80 ℃ (as shown in FIG. 3).
3. Akk preparation method of fungus capsule
3.1 weighing 60% of conjugated linoleic acid, 15% of L-carnitine and 25% of Akk bacteria by weight percent, placing the materials in a mixing tank, and uniformly stirring. Grinding the uniformly stirred conjugated linoleic acid, L-carnitine and Akk bacteria in a colloid mill for three times, sieving with a 100-mesh sieve to obtain a content material, placing the content material in a vacuum pan, controlling the vacuum degree to be-0.06 Mpa, and removing gas from the material (as shown in figure 4).
3.2 weighing the gelatin, the water and the glycerol according to the proportion of 100:40:100, feeding the materials into a gelatin melting tank, stirring and heating to 60-75 ℃, carrying out vacuum pumping under reduced pressure after the gelatin is completely melted, sieving by a 80-mesh sieve to obtain capsule body filtrate, and placing the capsule body filtrate in a heat-preserving barrel for later use (as shown in figure 5).
3.3 the obtained capsule body filtrate and the obtained content materials are respectively sent into a pelleting press according to the weight ratio of 1:2, and soft capsules are obtained by pressing. Controlling the temperature at 24-28 deg.C and humidity at 30-40%, statically drying for 24 hr, and making into pill. The obtained capsule is washed with above 90% ethanol to remove oil stain on the surface of the capsule. Selecting the capsule with oil on the surface, removing non-positive pellet to obtain positive soft capsule, and storing at 2-8 deg.C (shown in figure 6).
Enters the intestinal tract of animals with metabolic diseases by oral administration to adjust and improve the composition of intestinal flora, thereby having good treatment effect on the animals with metabolic diseases.
Example 2
The preparation method of the Akk bacteria capsule for animals related to metabolic diseases provided by the embodiment of the invention comprises the following steps:
1: akk extraction and pure culture of fungus
Fresh fecal samples of healthy people were separately collected in a polyethylene bag and stored in a sealed condition for future use, and 0.5g of feces was diluted into 9ml of sterile anaerobic ringer's solution containing 0.5g of cysteine. This suspension was mixed well and serially diluted (10-fold) in ringer's solution. Each dilution (1ml) was then inoculated in triplicate into 9ml of bicarbonate buffer. The basic culture medium contains: 0.4g of monopotassium phosphate, 0.53g of sodium monohydrogen phosphate, 0.3g of ammonium chloride, 0.3g of sodium chloride, 0.1g of magnesium chloride hexahydrate, 0.11g of calcium chloride, 1ml of alkaline trace element solution, 1ml of acidic trace element solution, 1ml of vitamin solution, 0.5mg of resazurin, 4g of sodium bicarbonate and 0.25g of sodium sulfide nonahydrate. To this basal medium 0.7% (v/v) of clear sterile rumen fluid and 0.25% (v/v) of commercial porcine gastric mucin were added and purified by ethanol precipitation. This medium is called mucin medium. Pure cultures were isolated using soft agar technique: the highest dilution of observed culture growth was serially diluted to 10 in phosphate buffer (pH7)-9Then 10 is put-6-10-9The dilutions were re-inoculated into the same medium containing 0.75% agar, individual target colonies were picked, allowed to grow in mucin medium, and re-inoculated into soft agar mucin medium. This step was repeated until purification (as shown in figure 2).
2: akk preparation method of fungus capsule
Weighing 60% of conjugated linoleic acid, 15% of L-carnitine and 25% of Akk bacteria according to the weight percentage, placing the materials into a mixing tank, and uniformly stirring the materials. Grinding the uniformly stirred conjugated linoleic acid, L-carnitine and Akk bacteria in a colloid mill for three times, sieving with a 100-mesh sieve to obtain a content material, placing the content material in a vacuum pan, controlling the vacuum degree to be-0.06 Mpa, and removing gas from the material (as shown in figure 4). Weighing gelatin, water and glycerol at a ratio of 100:40:100, feeding into a gelatin melting tank, stirring and heating to 60-75 deg.C, melting gelatin completely, vacuum-pumping under reduced pressure, sieving with 80 mesh sieve to obtain capsule filtrate, and placing in a heat-insulating bucket (shown in figure 5). And respectively feeding the obtained capsule body filtrate and the obtained content materials into a pelleting press according to the weight ratio of 1:2, and pressing to obtain the soft capsule. Controlling the temperature at 24-28 deg.C and humidity at 30-40%, statically drying for 24 hr, and making into pill. The obtained capsule is washed with above 90% ethanol to remove oil stain on the surface of the capsule. Selecting the capsule with oil on the surface, removing non-positive pellet to obtain positive soft capsule, and storing at 2-8 deg.C (shown in figure 6).
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911355192.7A CN110960558A (en) | 2019-12-25 | 2019-12-25 | A kind of preparation method of Akk bacteria animal capsules related to metabolic diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911355192.7A CN110960558A (en) | 2019-12-25 | 2019-12-25 | A kind of preparation method of Akk bacteria animal capsules related to metabolic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110960558A true CN110960558A (en) | 2020-04-07 |
Family
ID=70036289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911355192.7A Pending CN110960558A (en) | 2019-12-25 | 2019-12-25 | A kind of preparation method of Akk bacteria animal capsules related to metabolic diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110960558A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188565A (en) * | 2011-04-09 | 2011-09-21 | 荣成百合生物技术有限公司 | Weight-losing soft capsules and preparation method thereof |
| EP2919796A1 (en) * | 2012-11-19 | 2015-09-23 | Université catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| CN107849093A (en) * | 2015-05-06 | 2018-03-27 | 瓦赫宁恩大学 | The method for cultivating Ackermam Salmonella |
| WO2019092896A1 (en) * | 2017-11-08 | 2019-05-16 | アサヒグループホールディングス株式会社 | Akkermansia muciniphila proliferation material |
| CN109810931A (en) * | 2019-04-03 | 2019-05-28 | 广州康泽医疗科技有限公司 | A kind of culture medium and its application method for cultivating thermophilic mucin Ackermam Salmonella |
-
2019
- 2019-12-25 CN CN201911355192.7A patent/CN110960558A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188565A (en) * | 2011-04-09 | 2011-09-21 | 荣成百合生物技术有限公司 | Weight-losing soft capsules and preparation method thereof |
| EP2919796A1 (en) * | 2012-11-19 | 2015-09-23 | Université catholique de Louvain | Use of akkermansia for treating metabolic disorders |
| CN107849093A (en) * | 2015-05-06 | 2018-03-27 | 瓦赫宁恩大学 | The method for cultivating Ackermam Salmonella |
| WO2019092896A1 (en) * | 2017-11-08 | 2019-05-16 | アサヒグループホールディングス株式会社 | Akkermansia muciniphila proliferation material |
| CN109810931A (en) * | 2019-04-03 | 2019-05-28 | 广州康泽医疗科技有限公司 | A kind of culture medium and its application method for cultivating thermophilic mucin Ackermam Salmonella |
Non-Patent Citations (3)
| Title |
|---|
| HUBERT PLOVIER等: "A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice", 《NATURE MEDICINE》 * |
| MURIEL DERRIEN等: "Akkermansia muciniphila gen. nov., sp. nov.,a human intestinal mucin-degrading bacterium", 《INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY》 * |
| 王磊等: "Akkermansia muciniphila的分离培养及其在不同人群的定植比较研究进展", 《食品科学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107523526B (en) | Lactobacillus reuteri and application thereof | |
| AU2016344770B2 (en) | Faecalibacterium prausnitzii and Desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases | |
| CN109055278A (en) | A kind of Lactobacillus rhamnosus JYLR-005 and its hypoglycemic product and application | |
| CN113308421A (en) | Lactobacillus plantarum BUFX and application thereof in metabolic syndrome | |
| CN112760247A (en) | Lactobacillus rhamnosus for preventing and/or treating diseases caused by genital tract flora disorder and/or bone loss | |
| CN111304134B (en) | Lactobacillus plantarum capable of effectively relieving diabetes | |
| CN114146101A (en) | Application of bifidobacterium animalis subsp lactis BLA80 in preparing medicine or food for regulating intestinal motility | |
| US20240350565A1 (en) | Postbiotic | |
| CN113322216A (en) | Lactobacillus paracasei B111H and application thereof in metabolic syndrome | |
| CN116376740A (en) | Bifidobacterium longum with blood sugar reducing effect and application thereof | |
| CN118421537B (en) | A strain of Lactobacillus plantarum GLP1-LP that promotes the secretion of glucagon-like peptide | |
| CN114164158A (en) | Bifidobacterium strain ZK-77 for inhibiting pathogenic bacteria, relieving inflammation, and balancing flora | |
| WO2021134740A1 (en) | Tibetan pig fecal microbiota capsule for relieving diarrhea in weaned piglet, and preparation method therefor | |
| CN110960558A (en) | A kind of preparation method of Akk bacteria animal capsules related to metabolic diseases | |
| JP5868519B2 (en) | Reuterin-producing Lactobacillus brevis | |
| CN117050914A (en) | Acremonium muciniphilum and application thereof in improving GLP-1 secretion | |
| CN114540257B (en) | Lactobacillus crispatus IOB901 and application thereof in aspects of reducing blood sugar and blood fat | |
| CN113604400B (en) | Novel lactobacillus YUYINGW with diabetes preventing or treating effect | |
| CN114395592B (en) | Preparation method, equipment and application of zymosan capable of improving intestinal flora | |
| CN117016672A (en) | Feed for inducing type 2 diabetes and application of feed in establishment of type 2 diabetes animal model | |
| CN113249264B (en) | Bifidobacterium adolescentis and application thereof in metabolic syndrome | |
| CN116855413A (en) | Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof | |
| CN114164157A (en) | Lactobacillus salivarius strain ZK-88 for inhibiting inflammation, relieving swelling and aching of gum, and improving oral flora balance | |
| JP2021019524A (en) | Method for producing fermentation broth containing short-chain fatty acids | |
| CN112852662A (en) | Efficacy and application of lactobacillus plantarum YZX21 for reducing blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200407 |